As the first study in the field of SLE to integrate GWAS, gene expression eQTLs, and pharmacogenomic data to explore drug targets, we conducted a systematic analysis of the causal associations between 5427 druggable genes and SLE risk, ultimately identifying five potential therapeutic targets (BLK, HIST1H3H, HSPA1A, IL12A, NEU1). Here, IL12A is linked to systemic lupus erythematosus.